Status:
COMPLETED
RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum
Lead Sponsor:
University Hospital, Tours
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Serine proteases belonging to the elastase family are mainly responsible for lung tissue destruction as observed during cystic fibrosis. But anti-inflammatory therapies based on systemic or aerosolize...
Eligibility Criteria
Inclusion
- cystic fibrosis disease
- with rhDNase treatment
Exclusion
- Acute push of the bronchopulmonary attack or hospitalization for treatment of the disease during 2 weeks previous
- Exposure to a antibiotherapy or treatment by corticoids
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00843817
Start Date
April 1 2009
End Date
April 1 2013
Last Update
March 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital - Tours
Tours, France